Tags

Type your tag names separated by a space and hit enter

Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics.
Am J Gastroenterol 2007; 102(5):951-6AJ

Abstract

OBJECTIVES

Helicobacter pylori is causally associated with gastritis and peptic ulcer diseases. Recent data (meta-analysis) have demonstrated that triple therapy with amoxicillin, clarithromycin, and a proton pump inhibitor has an eradication rate of only 74-76% and new therapeutic protocols may be necessary. The aim of this study was to examine whether adding bovine lactoferrin (bLf) and probiotics (Pbs) to the standard triple therapy for H. pylori infection could improve the eradication rate and reduce side effects.

METHODS

H. pylori infection was diagnosed in 206 patients: in 107 based on an upper endoscopy exam and a rapid urease test, and in 99 by means of the H. pylori stool antigen-test and the C(13) urea breath test (C(13) UBT). The patients were randomized into two groups: 101 patients (group A) underwent standard triple eradication therapy (esomeprazole, clarithromycin, amoxicillin), while 105 patients (group B) underwent a modified eradication therapy (standard triple eradication therapy plus bLf and Pb). Successful eradication therapy was defined as a negative C(13) UBT 8 wk after completion of the treatment. Results were evaluated by intention-to-treat (ITT) and per-protocol (PP) analysis. Data were evaluated and considered positive when P<0.05.

RESULTS

At the end of the study 175/206 patients showed negative C(13) UBT results. According to intention-to-treat analysis, the infection was eradicated in 73/101 patients from Group A and in 93/105 from Group B. PP analysis showed 73/96 patients from Group A and 93/101 from Group B to have been successfully treated. More patients from group A than from group B reported side effects from their treatment (P<0.05).

CONCLUSIONS

The results of our study suggest that the addition of bLf and Pbs could improve the standard eradication therapy for H. pylori infection--bLf serving to increase the eradication rate and Pbs to reduce the side effects of antibiotic therapy.

Authors+Show Affiliations

Department of Medical and Surgical Gastroenterology, University of Pisa, Pisa, Italy.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

17313499

Citation

de Bortoli, Nicola, et al. "Helicobacter Pylori Eradication: a Randomized Prospective Study of Triple Therapy Versus Triple Therapy Plus Lactoferrin and Probiotics." The American Journal of Gastroenterology, vol. 102, no. 5, 2007, pp. 951-6.
de Bortoli N, Leonardi G, Ciancia E, et al. Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. Am J Gastroenterol. 2007;102(5):951-6.
de Bortoli, N., Leonardi, G., Ciancia, E., Merlo, A., Bellini, M., Costa, F., ... Marchi, S. (2007). Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. The American Journal of Gastroenterology, 102(5), pp. 951-6.
de Bortoli N, et al. Helicobacter Pylori Eradication: a Randomized Prospective Study of Triple Therapy Versus Triple Therapy Plus Lactoferrin and Probiotics. Am J Gastroenterol. 2007;102(5):951-6. PubMed PMID: 17313499.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. AU - de Bortoli,Nicola, AU - Leonardi,Giulia, AU - Ciancia,Eugenio, AU - Merlo,Andrea, AU - Bellini,Massimo, AU - Costa,Francesco, AU - Mumolo,Maria Gloria, AU - Ricchiuti,Angelo, AU - Cristiani,Fabrizio, AU - Santi,Stefano, AU - Rossi,Mauro, AU - Marchi,Santino, Y1 - 2007/02/21/ PY - 2007/2/23/pubmed PY - 2007/6/29/medline PY - 2007/2/23/entrez SP - 951 EP - 6 JF - The American journal of gastroenterology JO - Am. J. Gastroenterol. VL - 102 IS - 5 N2 - OBJECTIVES: Helicobacter pylori is causally associated with gastritis and peptic ulcer diseases. Recent data (meta-analysis) have demonstrated that triple therapy with amoxicillin, clarithromycin, and a proton pump inhibitor has an eradication rate of only 74-76% and new therapeutic protocols may be necessary. The aim of this study was to examine whether adding bovine lactoferrin (bLf) and probiotics (Pbs) to the standard triple therapy for H. pylori infection could improve the eradication rate and reduce side effects. METHODS: H. pylori infection was diagnosed in 206 patients: in 107 based on an upper endoscopy exam and a rapid urease test, and in 99 by means of the H. pylori stool antigen-test and the C(13) urea breath test (C(13) UBT). The patients were randomized into two groups: 101 patients (group A) underwent standard triple eradication therapy (esomeprazole, clarithromycin, amoxicillin), while 105 patients (group B) underwent a modified eradication therapy (standard triple eradication therapy plus bLf and Pb). Successful eradication therapy was defined as a negative C(13) UBT 8 wk after completion of the treatment. Results were evaluated by intention-to-treat (ITT) and per-protocol (PP) analysis. Data were evaluated and considered positive when P<0.05. RESULTS: At the end of the study 175/206 patients showed negative C(13) UBT results. According to intention-to-treat analysis, the infection was eradicated in 73/101 patients from Group A and in 93/105 from Group B. PP analysis showed 73/96 patients from Group A and 93/101 from Group B to have been successfully treated. More patients from group A than from group B reported side effects from their treatment (P<0.05). CONCLUSIONS: The results of our study suggest that the addition of bLf and Pbs could improve the standard eradication therapy for H. pylori infection--bLf serving to increase the eradication rate and Pbs to reduce the side effects of antibiotic therapy. SN - 0002-9270 UR - https://www.unboundmedicine.com/medline/citation/17313499/Helicobacter_pylori_eradication:_a_randomized_prospective_study_of_triple_therapy_versus_triple_therapy_plus_lactoferrin_and_probiotics_ L2 - http://Insights.ovid.com/pubmed?pmid=17313499 DB - PRIME DP - Unbound Medicine ER -